HPGC Renmintongtai Pharmaceutical Corporation's low P/E ratio may be due to anticipated significant degradation in earnings performance. The company's recent three-year growth being lower than market forecast also contributes to the low P/E. These trends may prevent a strong rise in share price soon.

The share price growth exceeds EPS growth, suggesting the market values the company's growth history. The recent superior company performance, and ongoing share price momentum indicate potential investor opportunities.